ABL2 Knockout HT29 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population designed to disrupt the ABL2 gene expression. This polyclonal format provides a heterogeneous mixture of edited cells, enabling robust loss-of-function studies without clonal selection artifacts. The gene disruption is achieved through CRISPR/Cas9-mediated targeting, generating a knockout model suitable for investigating ABL2 function in colorectal adenocarcinoma biology.
The host cell line HT29 is a well-characterized human colorectal adenocarcinoma epithelial cell line originally isolated from a 44-year-old Caucasian female. HT29 cells are widely used for in vitro studies of colorectal cancer, including cell adhesion, migration, and drug response assays. Their epithelial morphology and tumorigenic properties make them an appropriate system for modeling intestinal epithelial cancer behavior and for evaluating molecular mechanisms underlying colorectal tumor progression.
ABL2, also known as ARG, is a non-receptor tyrosine kinase that plays a pivotal role in cytoskeletal remodeling and signal transduction. It is activated downstream of growth factor receptors such as EGFR and PDGFR and through integrin engagement, integrating signals from the extracellular matrix. ABL2 is regulated by Src family kinases and F-actin, and it phosphorylates key substrates including cortactin, Crk, and p130Cas. It forms complexes with Crk, C3G, Abi1, and the WAVE2 complex, ultimately promoting actin polymerization through the Rac1/PAK pathway. This kinase thereby links receptor and adhesion signaling to dynamic reorganization of the actin cytoskeleton, a process essential for cell migration and invasive behavior.
In the context of HT29 colorectal adenocarcinoma cells, ABL2 disruption provides a critical model to dissect the mechanisms driving tumor cell migration and invasion. Given HT29 cells’ utility in studying colorectal cancer metastasis, the ABL2 knockout population enables precise investigation of how loss of this kinase affects integrin-mediated adhesion, growth factor-induced actin remodeling, and Rac1-dependent motility. This model is particularly valuable for exploring resistance mechanisms to targeted therapies that impinge on these pathways and for identifying downstream effectors that sustain malignancy.
Research applications for ABL2 Knockout HT29 Polyclonal Cells include detailed analyses of cell migration via wound healing and transwell migration/invasion assays, cytoskeletal dynamics using immunofluorescence staining for F-actin, and protein?Cprotein interactions through co-immunoprecipitation of ABL2 interactors such as p130Cas and Crk. Western blotting can assess ABL2 protein levels and phospho-tyrosine substrates, while phospho-signaling arrays enable pathway analysis. These cells are suitable for studying drug resistance mechanisms, tumor invasion, and the role of ABL2 in integrin and growth factor receptor crosstalk. For further technical information or customized support, please contact Ascent Research.
